Drug intelligence / Profile preview

KV23c

Development stage: Unknown
Lead developer: Kensana Health
Modality: Small Molecules

Overview

KV23c is a full-spectrum cannabinoid phytopharmaceutical developed by Kensana Health. It is designed to modulate the endocannabinoid system (ECS) to promote wound healing and address inflammatory processes. The drug is currently in Phase 3 clinical development for the treatment of calciphylaxis (specifically in the BEAT-Calci trial in collaboration with the University of Sydney), a rare and severe condition involving vascular calcification and skin necrosis. Additionally, KV23c is being explored in preclinical stages for the treatment of venous leg ulcers.

Other names: Kensana ECS Wound TherapyBEAT-Calci

Beyond the preview

Go deeper on KV23c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV23c.

Explore the full profile